Effect of Sitagliptin and Glimepiride on Glucose Homeostasis and cAMP Levels in Peripheral Tissues of HFD/STZ Diabetic Rats

Mohamed I Saad^1, , Maher A Kamel¹, Mervat Y Hanafi¹, Madiha H Helmy¹ and Rowaida R Shehata²

¹Department of Biochemistry, Medical Research Institute, Alexandria University, Egypt

²Department of Pharmacology, Medical Research Institute, Alexandria University, Egypt

Cite this paper:
Mohamed I Saad, Maher A Kamel, Mervat Y Hanafi, Madiha H Helmy and Rowaida R Shehata. Effect of Sitagliptin and Glimepiride on Glucose Homeostasis and cAMP Levels in Peripheral Tissues of HFD/STZ Diabetic Rats. American Journal of Biomedical Research. 2014; 2(3):52-60. doi: 10.12691/ajbr-2-3-3

Abstract

Introduction: T2DM is a group of metabolic disorders manifested by hyperglycemia as a result of insulin insufficiency and/or resistance. The main goal of antidiabetic therapies is to lower glucose levels, and therefore prevent development of diabetes complications. DPP-4 inhibitors (e.g. sitagliptin) are relatively new antidiabetic drugs which inhibit the activity of DPP-4 enzyme and therefore prevent rapid degradation of incretin hormones. Objective: We investigated effects of sitagliptin on glucose homeostasis, lipid profile, and insulin signaling by determination of cAMP levels in peripheral tissues of HFD/STZ diabetic rats, compared to glimepiride. Methods: The experimental rats were divided into five groups, each group comprising 10 rats. Group (1) served as the normal control rats and administered DMSO (without treatments) as the vehicle. The rest of the groups were rendered diabetic by feeding HFD containing 40% fats for 4 weeks, followed by a single I.P. injection of STZ (45 mg/kg of body weight). One week after STZ injection, the rats with FBG level of ≥ 200 mg/dl were considered diabetic. Group (2) served as the diabetic untreated rats and administered DMSO (without treatments) as the vehicle. Group (3) served as diabetic rats treated with glimepiride (0.1 mg/kg of body weight). Group (4) and group (5) served as diabetic rats treated with sitagliptin (10 and 30 mg/kg of body weight, respectively). Treatments were dissolved in DMSO and were given orally for 4 weeks. At the end of the treatment period, the blood, liver and adipose tissues (White and brown) were collected for biochemical analysis. Results: In normal control rats, the highest content of cAMP was observed in BAT. Diabetic rats showed an elevation in cAMP levels of liver and WAT to be 1.3 and 3.9 fold control values, respectively, while in BAT, cAMP level decreased to be 0.4 fold control value. Sitagliptin and glimepiride significantly decreased cAMP levels in liver and WAT. Conclusion: We conclude that sitagliptin and glimepiride have comparable effects on glucose homeostasis. Both drugs have cAMP-lowering effect which may suggest their potential protecting effect against vascular complications of diabetes.

Keywords:
diabetes DPP-4 inhibitors sitagliptin glimepiride cAMP

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Lin Y., Sun Z. Current views on type 2 diabetes. J Endocrinol 2010, 204 (1): 1-11.
[2]	Brass B.J., Abelev Z., Liao E.P., Poretsky L. Endocrine Pancreas. In Principles of Diabetes Mellitus. 2nd edition. Edited by Poretsky L. New York: Springer; 2010: 37-55.
[3]	Wu X., Garvey W.T. Insulin Action. In Textbook of Diabetes. 4th edition. Edited by Holt R.I.G., Cockram C.S., Flyvbjerg A., Goldstein R.J. Singapore: Wiley Blackwell; 2010: 104-125.
[4]	Ciaraldi T.P. Cellular Mechanisms of Insulin Action. In Principles of Diabetes Mellitus. 2nd edition. Edited by Poretsky L. New York: Springer; 2010: 75-87.
[5]	Gesta S., Tseng Y.H., Kahn C.R. Developmental origin of fat: tracking obesity to its source. Cell 2007, 131: 242-256.
[6]	Sell H., Deshaies Y., Richard D. The brown adipocyte: update on its metabolic role. Int J Biochem Cell Biol 2004, 36 (11): 2098-2104.
[7]	Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368 (9548): 1696-1705.
[8]	Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3: 153-165.
[9]	Srinivasan K., Viswanad B., Asrat L., Kaul C.L., Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005, 52: 313-320.
[10]	Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurements with Folin-phenol reagent. J Biol Chem 1951, 193: 265-270.
[11]	White M.F. Insulin signaling in health and disease. Science 2003, 302 (5651): 1710-1711.
[12]	Kahn S.E., Cooper M.E., Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014, 383 (9922): 1068-1083.
[13]	Pirola L., Johnston A.M., Van Obberghen E. Modulation of insulin action. Diabetologia 2004, 47: 170-184.
[14]	Reaven G.M. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005, 47: 201-210.
[15]	Bryan J., Crane A., Vila-Carriles W.H., Babenko AP.., Aguilar-Bryan L. Insulin secretagogues, sulfonylurea receptors and K (ATP) channels. Curr Pharm Des 2005, 11: 2699-2716.
[16]	Jackson J.E., Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs 1981, 22: 295-320.
[17]	Jackson J.E., Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1. Drugs 1981, 22: 211-245.
[18]	Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., Zinman B.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32: 193-203.
[19]	Chahil T.J., Ginsberg H.N. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006, 35: 491-510.
[20]	Mooradian A.D. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009, 5 (3): 150-159.
[21]	Addison D., Aguilar D. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr Atheroscler Rep 2011, 13 (2): 115-122.
[22]	Lu Y.L., Zhou D.Q., Zhai H.L., Wu H., Guo Z.K. Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin. Chin Med J 2012, 125 (10): 1690-1694.
[23]	Müller G., Wied S., Wetekam E.M., Crecelius A., Unkelbach A., Pünter J. Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulphonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade. Biochem Pharmacol 1994, 30 (48): 985-996.
[24]	Magnusson I., Rothman D., Gerard D., Katz L., Shulman G. Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 1995, 44: 185-189.
[25]	Ballard K., Malmfors T., Rosell S. Adrenergic innervation and vascular patterns in canine adipose tissue. Microvasc Res 1974, 8: 164-171.
[26]	Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006, 6: 177-181.
[27]	Hausberg M., Morgan D.A., Mitchell J.L., Sivitz W.I., Mark A.L., Haynes W.G. Leptin potentiates thermogenic sympathetic responses to hypothermia: a receptor-mediated effect. Diabetes 2002, 51: 2434-2440.
[28]	Lafontan M., Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993, 34: 1057-1091.
[29]	Sell H., Deshaies Y., Richard D. The brown adipocyte: update on its metabolic role. Int J Biochem Cell Biol 2004, 36: 2098-104.
[30]	Orava J., Nuutila P., Lidell M.E., Oikonen V., Noponen T., Viljanen T., Scheinin M., Taittonen M., Niemi T., Enerback S., Virtanen K.A. Different metabolic responses of human brown adipose tissue to activation by cold and insulin. Cell metabolism 2011, 14 (2): 272-279.